Liquidia Posts $2.64 Loss Per Share for Third Quarter
LQDA has more than doubled off its 52-week low of $22.31.
Summary
Liquidia reported a third-quarter loss of $2.64 per share, against an IBES estimate of USD 0.96, a swing to red ink after the company posted $74.7M of net income on $170.4M of YUTREPIA sales in Q2 2026. The headline carries no revenue figure, so the size of any top-line miss or beat is not yet clear. The quarter is the first full period since the October settlement with United Therapeutics, under which Liquidia paid $380.7M net to resolve all six lawsuits and preserve YUTREPIA's PAH indication. That cash outlay and the loss together put the balance sheet front and center for a company with a roughly $4.3B market value trading near $50 a share.
At the time of this announcement, LQDA was trading at $50.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $22.31 to $93.61. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.